araag2/HINT huggingface dataset:
Clinical trial NCT01144416 (phase 3, status: completed)
Conditions: infertility
ICD codes: N46.8, N46.9, N97.9, N97.0, N97.1, N97.2, N97.8
Drugs: placebo for sch 900962, placebo for recfsh
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Willing and able to provide written informed consent for trial P06029 as well as for
             the Frozen-Thawed Embryo Transfer (FTET) follow-up trial P06031, and for the
             pharmacogenetic analysis (if applicable).

          -  Female and >=35 to <=42 years of age with indication for COS and IVF/ICSI.

          -  Body weight ≥50.0 kg, body mass index (BMI) >=18.0 to <=32.0 kg/m2.

          -  Regular spontaneous menstrual cycle with variation not outside the 24-35 days.

          -  Ejaculatory sperm must be available (donated and/or cryopreserved sperm is allowed).

          -  Results of clinical laboratory tests, cervical smear, physical examination within
             normal limits or clinically acceptable to the investigator.

          -  Adhere to trial schedule.

        Exclusion Criteria:

          -  A recent history of/or any current endocrine abnormality.

          -  A history of ovarian hyper-response or ovarian hyperstimulation syndrome (OHSS).

          -  A history of/or current polycystic ovary syndrome.

          -  More than 20 basal antral follicles <11 mm (both ovaries combined) in the early
             follicular phase.

          -  Less than 2 ovaries or any other ovarian abnormality.

          -  Unilateral or bilateral hydrosalpinx.

          -  Intrauterine fibroids ≥5 cm or any clinically relevant pathology, which could impair
             embryo implantation or pregnancy continuation.

          -  More than three unsuccessful COS cycles for IVF/ICSI since the last established
             ongoing pregnancy (if applicable).

          -  A history of non- or low ovarian response to FSH/human menopausal gonadotropin (hMG)
             treatment.

          -  A history of recurrent miscarriage.

          -  FSH >15.0 IU/L or luteinizing hormone (LH) >12.0 IU/L during the early follicular
             phase.

          -  Positive for human immunodeficiency virus (HIV) or Hepatitis B.

          -  Contraindications for the use of gonadotropins or gonadotropin releasing hormone
             (GnRH) antagonists.

          -  A recent history of/or current epilepsy, thrombophilia, diabetes, cardiovascular,
             gastro-intestinal, hepatic, renal or pulmonary or auto-immune disease requiring
             regular treatment.

          -  Smoking or recently stopped smoking (ie, within the last 3 months prior to signing
             informed consent).

          -  A recent history or presence of alcohol or drug abuse.

          -  The participant or the sperm donor has known gene defects, genetic abnormalities, or
             abnormal karyotyping, relevant for the current indication or for the health of the
             offspring.

          -  Prior or concomitant medications disallowed by protocol.
Clinical trial NCT01536691 (phase 3, status: unknown status)
Conditions: cancer, malignancy
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: ramosetron, ondansetron
SMILES: CN1C=C(C(=O)[C@@H]2CCC3=C(C2)N=CN3)C2=C1C=CC=C2, CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2
Eligibility criteria:

        Inclusion Criteria:

          1. Patients diagnosed as malignancy who will be treated with highly emetogenic
             chemotherapeutic agents (NCCN guideline v1.0 2011 anti-emesis), over 20 years and both
             sex

          2. ECOG performance status 0-2

          3. Available oral administration of study drugs

          4. Patients must sign an informed consent indicating that they are aware of the
             investigational nature of the study in keeping with the policy of the hospital

        Exclusion Criteria:

          1. Severe Hypertension, severe Heart disease, kidney disease (serum creatinine > 3
             mg/dl), liver disease (AST, ALT > 3 times of upper normal range, ALP > 2 times of
             upper normal range)

          2. Patients with GI obstruction, active gastric ulcer or other diseases that could
             provoke nausea and vomiting

          3. Patients who have nausea and vomiting within 1 week before chemotherapy

          4. Patients who should take steroid, antiemetics, pimozide, terfenadine, astemizole,
             cisapride, rifampin, carbamazepine, phenytoin, ketoconazole, itraconazole, nefazodone,
             troleandomycin, clarithromycin, ritonavir or nelfinavir for the treatment of other
             diseases

          5. Patients with brain tumor, brain metastasis or seizure

          6. Patients receiving chemotherapy within 12 months before enrollment

          7. Patients who need radiation therapy during study period or receiving radiation therapy
             within 2 weeks before chemotherapy

          8. Patients who have known allergy or severe side effect on study drugs

          9. Pregnant or lactating women, or women who wish to become pregnant

         10. Others whom the investigator judges inappropriate as subjects for this study
Clinical trial NCT00346034 (phase 3, status: completed)
Conditions: fibromyalgia
ICD codes: M79.7
Drugs: pregabalin
SMILES: NCC1(CC(O)=O)CCCCC1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have met the inclusion criteria for the preceding fibromyalgia Protocol
             A0081100, and must have received pregabalin/placebo under double-blind conditions.

        Exclusion Criteria:

          -  Patients may not participate in the study if they experienced a serious adverse event
             during the previous fibromyalgia Study A0081100 which was determined to be related to
             the study medication by the investigator or the sponsor.
Clinical trial NCT03047954 (phase 3, status: completed)
Conditions: atopic dermatitis
ICD codes: L20.89, L20.9
Drugs: broncho-vaxom, placebo - cap
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female children aged 6 months to 7 years (in eighth year of life)

          -  Children with Atopic Dermatitis (Hanifin-Rajka or Williams et al criteria) with
             affected body surface area ≥15% and ≤ 70%

          -  25 ≤ SCORAD ≤ 70

          -  Written informed consent obtained from the parents/legal Guardian (and the child if
             applicable)

        Exclusion Criteria:

          -  Children under general corticotherapy within one month of study start

          -  Children with immunodeficiency

          -  Children with malignant disease

          -  Children with SCORAD<25 or >70

          -  Children with affected body surface area < 15% or >70%

          -  Children with autoimmune disease

          -  Children under immunosuppressive or immunostimulating therapy within 1 month of study
             start

          -  Children whose parents or Guardians are unable to comply with the requirements of the
             protocol e.g.completion of patient's diary card

          -  Children with a known allergy or previous intolerance or known hypersensitivity to the
             trial drug or any of the corticoids used

          -  Participation in another clinical trial and/or treatment with an experimental drug
             within 3 months of study start and during present trial
Clinical trial NCT01484210 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: elpenhaler active - diskus placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  age 18-65 years,

          -  diagnosis of asthma of 6 months,

          -  FEV1 ≥ 50% and ≤ 80% predicted,

          -  reversibility of at least 12%,

          -  stable asthma for at least 4 weeks,

          -  inhaled steroids (ICS) at a stable dose within the previous 30 days,

          -  PIF 30 - 90 lt/min and

          -  informed consent.

        Exclusion Criteria:

          -  history of other pulmonary disease,

          -  asthma exacerbation or respiratory infection within the previous 4 weeks,

          -  hospitalization for acute asthmatic symptoms requiring parenteral steroids or oral
             steroid dose increase, within the previous 30 days,

          -  heavy smokers,

          -  change of asthma medication within the previous 4 weeks,

          -  seasonal asthma alone,

          -  history of severe heart disease,

          -  pregnancy or lactation,

          -  use of a β-blocker, of a NSAID or an antiallergic/antihistaminic medication within 2
             weeks prior to screening visit.
Clinical trial NCT00202969 (phase 3, status: completed)
Conditions: gastric cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: s-1, s-1 plus cddp, 5-fu plus cddp
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Non-prior chemotherapy treated advanced gastric adenocarcinoma

          -  Age 18 and over

          -  Performance status 0, 1, or 2 (ECOG)

          -  Life expectancy 3 months

          -  Hematopoietic WBC lower limit of normal-12,000/mm^3 Absolute granulocyte count ≥
             2,000/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 8.0 g/dL

          -  Hepatic AST and ALT ≤ 100 U/L ALP ≤ 2 times upper limit of normal (ULN) Bilirubin ≤
             1.5 mg/dL

          -  Renal Plasma creatinine ≤ ULN Creatinine clearance ≥ 60 mL/min

        Exclusion Criteria:

          -  Interstitial pneumonia, pulmonary fibrosis

          -  Myocardial infarction within the last 6 months, severe/unstable angina, congestive
             heart failure

          -  Intestinal paralysis, intestinal obstruction, uncontrollable diabetes
Clinical trial NCT00373113 (phase 3, status: terminated)
Conditions: breast neoplasms
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: capecitabine, sunitinib malate
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
Reason stopped: 
    see termination reason in detailed description.
  
Eligibility criteria:

        Inclusion Criteria:

          -  breast adenocarcinoma

          -  prior treatment with an anthracycline and a taxane either concurrently or sequentially
             in the neoadjuvant, adjuvant and or/ advanced disease treatment settings. No more than
             1 chemotherapy regimen in the advanced setting

        Exclusion Criteria:

          -  Prior treatment with regimens of chemotherapy in the advanced/metastatic disease
             setting beyond those containing anthracyclines and taxanes or multiple anthracyclines/
             taxanes treatments.

          -  Any prior regimen with capecitabine
Clinical trial NCT00285012 (phase 3, status: completed)
Conditions: smoking cessation
ICD codes: Y36.881S, Y36.891S, Y36.880S, Y36.881A, Y36.881D, Y36.890S, Y36.891A
Drugs: placebo, varenicline tartarate
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@]12C[C@]([H])(CNC1)C1=CC3=NC=CN=C3C=C21
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects will be current cigarette smokers who have smoked an average of at least 10
             cigarettes per day during the past year and during the month prior to the screening
             visit.

          -  mild to moderate COPD confirmed by spirometry

          -  Subjects must have a clinical diagnosis of COPD.

        Exclusion Criteria:

          -  Subjects who have made a serious attempt to quit smoking in the past 3 months.

          -  Subjects who have been previously randomized in a study that has included varenicline.
Clinical trial NCT01365455 (phase 3, status: completed)
Conditions: moderate to severe plaque-type psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: secukinumab 150 mg, placebo to secukinumab 150 mg
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          -  Moderate and severe plaque-type psoriasis diagnosed for at least 6 months.

          -  Severity of psoriasis disease meeting all of the following three criteria:

          -  Psoriasis Area and Severity Index (PASI) score of 12 or greater,

          -  Investigator's Global Assessment (IGA) score of 3 or greater,

          -  Total body surface area (BSA) affected of 10% or greater.

          -  Inadequate control by prior use of topical treatment, phototherapy and/or systemic
             therapy.

        Exclusion criteria:

          -  Current forms of psoriasis other than chronic plaque-type psoriasis (for example,
             pustular, erythrodermic, guttate).

          -  Current drug-induced psoriasis.

          -  Previous use of secukinumab or any drug that targets IL-17 or IL-17 receptor.

          -  Significant medical problems such as uncontrolled hypertension, congestive heart
             failure or a condition that significantly immunocompromises the subject.

          -  Hematological abnormalities.

          -  History of an ongoing, chronic or recurrent infectious disease, or evidence of
             untreated tuberculosis.

          -  History of lymphoproliferative disease or history of malignancy of any organ system
             within the past 5 years.

          -  Pregnant or nursing (lactating) women.

          -  Subjects not willing to limit UV light exposure during the study Other
             protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT01112267 (phase 3, status: completed)
Conditions: low back pain
ICD codes: M54.50, M54.51, M54.59
Drugs: tramadol hcl/acetaminophen extended release, placebo, tramadol hcl/acetaminophen extended release, placebo
SMILES: COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Participants diagnosed with low back pain at least 3 months before the screening or
             washout period

          -  Participants who have taken a stable dose of Non-Steroidal Anti-Inflammatory Drugs
             (NSAIDs) (drugs used for reducing inflammation and pain ) or Cyclo-Oxygenase 2 (COX-2)
             selective inhibitors (an anti-inflammatory drug that fights pain) from 7 days before
             investigational product administration, and could maintain the same dose during the
             period of the study

          -  Participants whose average pain intensity is more than or equal to 4.0 centimeters on
             Visual Analog Scale over the last 48 hours after the completion of screening

          -  Postmenopausal or surgically sterile or abstinent women or practicing a highly
             effective method of birth control

          -  Women with childbearing potential must have negative pregnancy test

        Exclusion Criteria:

          -  Participants who have taken tramadol or tramadol HCl or acetaminophen, or narcotic
             (strong habit-forming drug that stops pain and depresses the central nervous system)
             analgesic tablet within 30 days before investigational product administration

          -  Participants who have taken acetaminophen tablet within 7 days before investigational
             product administration

          -  Participants with tumor or infection in meninges or spinal cord

          -  Participants who have fibromyalgia (neurosensory disorder characterized by muscle
             pain, joint stiffness, and fatigue), reflex sympathetic dystrophy (feeling of pain
             associated with evidence of minor nerve injury) or causalgia (persistent, severe
             burning sensation of the skin), acute spinal cord compression, acute nerve root
             compression, severe lower extremity weakness or numbness, regional pain syndrome,
             meningitis (inflammation of the meninges), diskitis (nonbacterial inflammation of an
             intervertebral disk or disk space), back pain because of secondary infection or tumor,
             or pain caused by a confirmed or suspected neoplasm

          -  Participants who have taken analgesic (including local agents or anesthetics),
             sedative-hypnotic (e.g., diazepam), or muscle relaxant other than a stable dose of
             NSAIDs or COX-2 selective inhibitors within 5 times the half-life of the concerned
             agent before investigational product administration
Clinical trial NCT00174720 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: ciclesonide (xrp1526)
SMILES: [H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(O[C@@H](O2)C1CCCCC1)C(=O)COC(=O)C(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Males or females 12 years or older

          -  History of persistent bronchial asthma for at least 6 months

          -  Documented use of bronchodilators (short acting only) only or methylxanthines for at
             least 1 month before screening

          -  At screening, FEV1 60 to 90% of predicted. Reversibility of FEV1 by at least 12%
             post-bronchodilator

          -  Be able to use oral inhalers

          -  Non-smokers

        Exclusion Criteria:

          -  History of life-threatening asthma

          -  Other pulmonary diseases

          -  URI within 4 weeks before screening

          -  Use of systemic steroids within 6 months before screening. Use of inhaled steroids
             within 30 days before screening. More than 2 in-patient hospitalizations or ER visits
             due to asthma exacerbations in the prior year before screening

          -  Pregnant or breast-feeding females

          -  Females of child-bearing potential not using adequate means of birth control

          -  Clinically relevant cardiovascular, hepatic, neurologic, endocrine, or other major
             systemic disease

          -  Abnormal clinical laboratory parameters that would limit participation in the study or
             interfere with interpretation of study results

          -  History of drug or alcohol abuse

          -  Treatment with any investigational product within 30 days prior to study entry
Clinical trial NCT00619840 (phase 3, status: completed)
Conditions: attention deficit hyperactivity disorder
ICD codes: F90.2, F90.8, F90.9, F90.0, F90.1
Drugs: methylphenidate hydrochloride, placebo
SMILES: COC(=O)C(C1CCCCN1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patient treated as outpatient or inpatient

          -  Patient has a good command of German

          -  Score of 85 or greater in the IQ test (MWT-B)

          -  Diagnosis of ADHD according to ADHD-CL (DSM IV) and WRI-WRAADDS > 28 points

          -  ADHD symptoms have existed since childhood (WURS-k >= 30)

          -  Body mass index >= 20

          -  Willing to eat breakfast

          -  Patient is willing and able to come to the observation appointments

          -  Written consent of the patient to participate in the study

        Exclusion Criteria:

          -  Treatment with psychostimulants in the past 2 weeks

          -  Inconsistencies in the CAARS- S:L >= 8 (Inconsistency Index)

          -  Shift work or night work

          -  Alcohol, medication or drug dependency in the past 6 months or manifest drug abuse

          -  Diagnosis of a psychosis (SKID-I)

          -  Epileptic attacks in the past

          -  EEG results which suggest epilepsy

          -  Clinically relevant liver disease

          -  Clinically relevant hyperthyroidism (relevantly elevated TSH, T4)

          -  Acute depressive episode according to ICD-10 F32.2 and ICD-10 32.3 (SKID-I)

          -  Illnesses with schizophrenic symptoms (SKID-I)

          -  Acute manic episode, bipolar disorder (SKID-I)

          -  Diagnosis of a tic disorder

          -  Acute anorexia

          -  Acute prominent panic disorder and generalised anxiety (SKID-I)

          -  Clinically relevant kidney disorders

          -  Known high blood pressure

          -  Known occlusive arterial disease

          -  Known angina pectoris

          -  Known coronary heart disease and state after myocardial infarction

          -  Known tachycardial arrhythmias

          -  Post-stroke status

          -  Known elevated intra-occular pressure

          -  Known enlarged prostates

          -  Participation in a clinical study within the past 30 days

          -  Participation in this study at an earlier point in time

          -  Simultaneous participation in another clinical trial

          -  Women of child-bearing age without adequate contraception

          -  Patients with terminal illness (e.g. cancer)

          -  Pregnancy (positive pregnancy test) or lactation period
Clinical trial NCT00426660 (phase 3, status: completed)
Conditions: hiv infections
ICD codes: Z21
Drugs: maraviroc
SMILES: CC(C)C1=NN=C(C)N1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects must be failing to achieve adequate virologic suppression on their current
             regimen and have HIV-1 RNA greater than or equal to 1000 copies/ml, at screening

          -  Have only R5 HIV-1 at Screening as verified by the Monogram Biosciences Trofile assay

          -  Minimum age must be 16 years or minimum adult age as determined by local regulatory
             authorities or directed by local law.

        Exclusion Criteria:

          -  Failed prior treatment with any CCR5 antagonist, in any ongoing CCR5 trial or having
             previously prematurely discontinued Maraviroc in trials
Clinical trial NCT00195273 (phase 3, status: completed)
Conditions: graft vs host disease, kidney transplantation
ICD codes: N26.2, Q63.0, Q63.2, Z52.4, I75.81, N19, N20.0
Drugs: sirolimus, cyclosporine, mycophenolate mofetil, corticosteroids, daclizumab
SMILES: CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Kidney transplantation

          -  Donor must be at least 60 years old.

        Exclusion Criteria:

          -  Current systemic infection

          -  Unstable angina or treatment for serious arrhythmia.

          -  Cancer within the previous 5 years.
Clinical trial NCT01156012 (phase 3, status: completed)
Conditions: glaucoma
ICD codes: H40.9, Q15.0, B73.02, H40.823, H40.89, H44.513, H40.821
Drugs: t2345, prostaglandin
SMILES: CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients diagnosed with glaucoma

        Exclusion Criteria:

          -  Under 18.